Immuno-Oncology Pioneer Dr. Michael Kalos Joins Kos Biotechnology Partners as Venture Partner
Former Eli Lilly Oncology CSO, co-inventor of the first CAR-T product Kos announced the third closing of its inaugural venture fund with $123 million in June 2026 NEW YORK and ATHENS, Greece, Sept. 10, 2026 /PRNewswire/ -- Kos Biotechnology Partners, a global life sciences investment...